Results 71 to 80 of about 8,676,773 (167)
Criteria for Gauging Response to Sodium Oxybate for Narcolepsy
Our objective was to define responder criteria using an anchor-based approach for frequency of cataplexy attacks and excessive daytime sleepiness in narcolepsy patients undergoing sodium oxybate treatment. We used pooled data from two randomized, placebo-
Terri E. Weaver (7931498) +2 more
core
Sodium oxybate (SO) is a GABAβ agonist used to treat the sleep disorder narcolepsy. SO was shown to increase slow wave sleep (SWS) and EEG delta power (0.75-4.5 Hz), both indexes of NREM sleep (NREMS) intensity and depth, suggesting that SO enhances ...
Schwartz, S. +13 more
core +1 more source
Introduction: Sodium oxybate is indicated for the treatment of Excessive Daytime Sleepiness (EDS) and cataplexy in patients with narcolepsy. The currently marketed product, an immediate release (IR) sodium oxybate is required to be taken twice nightly ...
Monteith, D +3 more
core +1 more source
Background: Narcolepsy is a chronical neurological disease with a prevalence of 0,02-0,05 % in the western world. A massive increase in incidence occurred after the vaccination with Pandemrix against the H1N1-influenza.
Björck, Per
core
Compatibility studies of Sodium oxybate oral solution
Nātrija oksibutirāta orālā šķīduma savietojamības pētījumi. Valtere L. K., darba vadītāji Dr. ķīm., prof. Vīksna A., Mg. ķīm. Kuprevičs K., bakalaura darbs, 68 lappuses, 33 literatūras avoti, 4 pielikumi. Latviešu valodā. Darbā tika veikti savietojamības
Valtere, Līva Klinta
core
Optimizing patient outcomes and empowering the patient-clinician partnership. [PDF]
Thorpy M.
europepmc +1 more source
Introduction: sodium oxybate and cardiovascular safety: reconciling 20 years of clinical and research experience with sodium intake guidelines. [PDF]
Kushida CA.
europepmc +1 more source
Sodium-Containing Pharmaceutical Products as Contributors to Cardiovascular Risk. [PDF]
White WB, Kovacs RJ.
europepmc +1 more source

